Clinical Trial Update: Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the combination of Tarlatamab with Temozolomide for glioma and other CNS tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumor
• Glioma

Drugs mentioned

• Tarlatamab
• Temozolomide (Temozolomide)

Snippet

Sponsor: Centre Leon Berard | Conditions: Glioma, CNS Tumor, Adult | Phase 1, Phase 2 | Status: RECRUITING